NumerixS Investment Technologies Inc lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 72.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,406 shares of the biopharmaceutical company’s stock after selling 6,365 shares during the quarter. NumerixS Investment Technologies Inc’s holdings in Gilead Sciences were worth $149,000 as of its most recent filing with the SEC.
Other institutional investors have also bought and sold shares of the company. BlackRock Inc. lifted its stake in shares of Gilead Sciences by 2.2% during the fourth quarter. BlackRock Inc. now owns 104,186,077 shares of the biopharmaceutical company’s stock valued at $6,516,839,000 after acquiring an additional 2,195,948 shares during the period. Vanguard Group Inc. lifted its stake in shares of Gilead Sciences by 1.1% during the third quarter. Vanguard Group Inc. now owns 97,167,329 shares of the biopharmaceutical company’s stock valued at $7,502,290,000 after acquiring an additional 1,071,619 shares during the period. Vanguard Group Inc lifted its stake in shares of Gilead Sciences by 1.1% during the third quarter. Vanguard Group Inc now owns 97,167,329 shares of the biopharmaceutical company’s stock valued at $7,502,290,000 after acquiring an additional 1,071,619 shares during the period. Capital Research Global Investors lifted its stake in shares of Gilead Sciences by 22.5% during the third quarter. Capital Research Global Investors now owns 69,854,968 shares of the biopharmaceutical company’s stock valued at $5,393,502,000 after acquiring an additional 12,818,301 shares during the period. Finally, Bank of New York Mellon Corp lifted its stake in shares of Gilead Sciences by 199,789.8% during the third quarter. Bank of New York Mellon Corp now owns 31,350,714 shares of the biopharmaceutical company’s stock valued at $2,420,587,000 after acquiring an additional 31,335,030 shares during the period. 79.13% of the stock is currently owned by institutional investors.
Several equities analysts have recently issued reports on the company. Zacks Investment Research lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, January 23rd. BidaskClub downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, November 21st. BMO Capital Markets initiated coverage on Gilead Sciences in a report on Thursday, March 14th. They issued an “outperform” rating and a $78.00 price target for the company. ValuEngine upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a report on Saturday, December 1st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $92.00 price objective on shares of Gilead Sciences in a report on Wednesday, December 19th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $82.29.
NASDAQ:GILD opened at $65.02 on Tuesday. The company has a quick ratio of 3.30, a current ratio of 3.38 and a debt-to-equity ratio of 1.19. The stock has a market cap of $83.71 billion, a P/E ratio of 10.57, a PEG ratio of 4.13 and a beta of 1.16. Gilead Sciences, Inc. has a 52-week low of $60.32 and a 52-week high of $79.61.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.70 by ($0.26). The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.52 billion. Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The firm’s quarterly revenue was down 2.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.78 earnings per share. On average, research analysts predict that Gilead Sciences, Inc. will post 6.23 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 28th. Investors of record on Friday, March 15th will be given a dividend of $0.63 per share. The ex-dividend date is Thursday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.57. This represents a $2.52 annualized dividend and a yield of 3.88%. Gilead Sciences’s dividend payout ratio is 40.98%.
In related news, Director Gayle E. Wilson sold 19,068 shares of the stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $67.08, for a total transaction of $1,279,081.44. Following the completion of the transaction, the director now directly owns 143,567 shares of the company’s stock, valued at $9,630,474.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.16% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2019/03/19/gilead-sciences-inc-gild-holdings-reduced-by-numerixs-investment-technologies-inc.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
Featured Story: What is the Stochastic Momentum Index (SMI)?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.